Okairos Company Profile

News Articles [ 8 Associated News Articles listed on BioPortfolio]

Aeras, University of Oxford, Okairos: TB, HIV and Malaria Vaccine Research Gets Major Boost (News)

Rockville, USA & Oxford, UK & Basel, Switzerland - Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company ...

Okairos Initiates Phase I Clinical Trial Evaluating Vaccine against RSV Infections

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infant...

T-cell vaccine specialist Okairos named by FierceBiotech as one of the 2012 Fierce 15

FierceBiotech today named Okairos as one of 2012's Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's...

Okairos Named as One of Windhover’s Top Projects to Watch in Infectious Diseases

Windhover Information has named Okairos as one of its Top Projects to Watch at the 4th Annual Therapeutic Area Partnerships, one of the biopharmaceutical industry’s premier part...

Okairos to commence novel RSV vaccine Phase I clinical trial

Okairos today announced the initiation of a Phase I clinical trial evaluating a vaccine against respiratory syncytial virus (RSV), a leading cause of hospital admissions in infants and children.

Aeras, Oxford University, Okairos: TB, HIV and Malaria Vaccine Research Gets Major Boost

$2.9 million Grant to Advance Chimpanzee Adenovirus Platform Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okair...

TB, HIV and malaria vaccine research gets major boost

(Burness Communications) Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announ...

Aeras receives grant to support the development of vaccines against TB, HIV and malaria

Aeras, a nonprofit biotech advancing TB vaccines for the world, the University of Oxford and Okairos, a biopharmaceutical company specializing in T-cell vaccines, today announced a $2.9 million grant...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [ 1 Associated Companies listed on BioPortfolio]

Okairos

Okairos is a clinical-stage biopharmaceutical company, developing genetic vaccines for major infectious diseases - including malaria, hepatitis C, influenza, respiratory syncytial...